サンプル依頼リスト カート
  • English
市場調査レポート
商品コード
1729116

原発性胆汁性胆管炎の世界市場の機会と戦略（～2034年）

Primary Biliary Cholangitis Global Market Opportunities And Strategies To 2034

出版日
ページ情報
英文 319 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.06円
原発性胆汁性胆管炎の世界市場の機会と戦略（～2034年）
出版日: 2025年05月20日
発行: The Business Research Company
ページ情報: 英文 319 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の原発性胆汁性胆管炎の市場規模は、2019年に7億3,321万米ドルであり、2024年まで5.00%を超えるCAGRで成長しました。

個別化医療に対する需要の高まり

過去の期間、個別化医療に対する需要の高まりが原発性胆汁性胆管炎市場の成長を支えました。個別化医療は、遺伝子、分子、臨床プロファイルに基づいて治療を調整し、原発性胆汁性胆管炎のより正確な治療を可能にします。オベチコール酸（OCA）は、ウルソデオキシコール酸（UDCA）のような従来の治療に代わる標的治療として機能しています。フィブラート系薬剤やFXR（ファルネソイドX受容体）作動薬を含む新しい治療法は、特定の患者群に対して評価されています。ファーマコゲノミクスは、有効性を予測し、副作用を最小化し、試行錯誤的な処方を減らすことによって治療を向上させます。このアプローチは、患者がもっとも効果的で個別化された治療を受けられるようにすることで、転帰を最適化します。例えば2022年10月、米国を拠点とする、科学者、患者、医療提供者を代表する組織であるPersonalized Medicine Coalitionは、患者と医療制度に利益をもたらす個別化医療の理解と採用を促進するため、複数のタイプのがん、遺伝的希少疾患、さまざまな慢性疾患や感染症の患者を対象に、7万5,000を超える遺伝子検査製品と300を超える個別化医薬品が市場に出回っていると推定しています。さらに、個別化医療を提唱する米国を拠点とする企業、Personalized Medicine Coalition（PMC）によると、2022年に米国食品医薬品局による新薬承認の34%を個別化医薬品が占めるようになり、過去8年間はいずれも承認の25%以上を個別化医薬品が占めています。

当レポートでは、世界の原発性胆汁性胆管炎市場について調査分析し、市場の特徴、各地域の市場規模と予測、競合情勢、市場機会と戦略などの情報を提供しています。

目次

第1章 エグゼクティブサマリー

  • 原発性胆汁性胆管炎 - 市場の魅力とマクロ経済情勢

第2章 目次

第3章 表のリスト

第4章 図のリスト

第5章 レポートの構成

第6章 市場の特徴

  • 一般的な市場の定義
  • サマリー
  • 原発性胆汁性胆管炎市場の定義とセグメンテーション
  • 市場のセグメンテーション：治療タイプ別
    • 薬剤
    • 肝移植
  • 市場のセグメンテーション：診断別
    • 磁気共鳴エラストグラフィ（MRE）
    • 磁気共鳴胆管膵管撮影（MRCP）
    • 超音波
    • フィブロスキャン
    • コレステロール検査
    • 抗体検査
    • 肝臓検査
    • その他の診断
  • 市場のセグメンテーション：エンドユーザー別
    • 病院
    • 専門クリニック
    • 在宅医療
    • その他のエンドユーザー

第7章 主な市場動向

  • 肝疾患管理における併用療法の役割
  • 胆汁酸アナログに基づく治療法の進歩
  • PBC治療における革新を推進する戦略的パートナーシップ

第8章 世界の原発性胆汁性胆管炎の成長分析と戦略分析フレームワーク

  • 世界の原発性胆汁性胆管炎に関するPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
  • 最終用途産業の分析
    • 病院、専門クリニック
    • 在宅医療
    • 診断検査室
    • 製薬・バイオテクノロジー企業
    • その他のエンドユーザー
  • 世界の原発性胆汁性胆管炎市場の成長率分析
  • 市場成長の実績（2019年～2024年）
    • 市場促進要因（2019年～2024年）
    • 市場抑制要因（2019年～2024年）
  • 市場成長の予測（2024年～2029年・2034年）
    • 市場促進要因（2024年～2029年）
    • 市場抑制要因（2024年～2029年）
  • 成長予測の寄与要因
    • 量的成長の寄与要因
    • 促進要因
    • 抑制要因
  • 世界の原発性胆汁性胆管炎の総市場規模（TAM）

第9章 世界の原発性胆汁性胆管炎市場のセグメンテーション

  • 世界の原発性胆汁性胆管炎市場：治療タイプ別、実績と予測（2019年～2024年・2029年・2034年）
  • 世界の原発性胆汁性胆管炎市場：診断別、実績と予測（2019年～2024年・2029年・2034年）
  • 世界の原発性胆汁性胆管炎市場：エンドユーザー別、実績と予測（2019年～2024年・2029年・2034年）
  • 世界の原発性胆汁性胆管炎市場、薬剤のサブセグメンテーション：タイプ別、実績と予測（2019年～2024年・2029年・2034年）
  • 世界の原発性胆汁性胆管炎市場、肝移植のサブセグメンテーション：タイプ別、実績と予測（2019年～2024年・2029年・2034年）

第10章 原発性胆汁性胆管炎市場、地域と国の分析

  • 世界の原発性胆汁性胆管炎市場：地域別、実績と予測（2019年～2024年・2029年・2034年）
  • 世界の原発性胆汁性胆管炎市場：国別、実績と予測（2019年～2024年・2029年・2034年）

第11章 アジア太平洋市場

第12章 西欧市場

第13章 東欧市場

第14章 北米市場

第15章 南米市場

第16章 中東市場

第17章 アフリカ市場

第18章 競合情勢と企業プロファイル

  • 企業プロファイル
  • Intercept Pharmaceuticals Inc.
  • Mayo Clinic Laboratories
  • University of Pittsburgh Medical Center (UPMC)
  • Stanford Health Care
  • Duke University Hospital

第19章 その他の主要企業と革新的企業

  • UCLA Medical Center
  • King's College Hospital
  • NewYork-Presbyterian Hospital
  • Cleveland Clinic
  • Johns Hopkins Hospital
  • GENFIT SA
  • Ipsen Pharma SA
  • Gilead Sciences Inc.
  • Ascletis Pharma Inc.
  • Calliditas Therapeutics AB
  • Cour Pharmaceutical
  • GlaxoSmithKline plc (GSK)
  • HighTide Biopharma Inc.
  • Mirum Pharmaceuticals Inc.
  • NGM Biopharmaceuticals Inc.

第20章 競合ベンチマーキング

第21章 競合ダッシュボード

第22章 主な合併と買収

  • Gilead Sciences Acquired CymaBay Therapeutics
  • Alfasigma Acquired Intercept Pharmaceuticals
  • Ipsen Acquired Albireo Pharma
  • Advanz Pharma Corp. Limited Acquired Intercept Pharmaceuticals

第23章 原発性胆汁性胆管炎市場の近年の発展

第24章 機会と戦略

  • 世界の原発性胆汁性胆管炎市場 - もっとも新たな機会を提供する国（2029年）
  • 世界の原発性胆汁性胆管炎市場 - もっとも新たな機会を提供するセグメント（2029年）
  • 世界の原発性胆汁性胆管炎市場 - 成長戦略（2029年）
    • 市場動向に基づく戦略
    • 競合の戦略

第25章 原発性胆汁性胆管炎市場：結論と提言

  • 結論
  • 提言
    • 製品
    • 流通
    • 価格
    • 販促
    • 人々

第26章 付録

目次
Product Code: o&s1561

Primary biliary cholangitis (PBC) is a chronic, progressive liver disease that primarily affects the bile ducts within the liver. It is an autoimmune condition in which the body's immune system mistakenly attacks the small bile ducts, leading to inflammation and scarring. Over time, this damage impairs bile flow, causing a buildup of toxic substances that can lead to liver fibrosis, cirrhosis and ultimately liver failure.

The primary biliary cholangitis market consists of sales by entities (organizations, sole traders and partnerships) of primary biliary cholangitis drugs and treatments that are used to treat PBC. PBC predominantly affects middle-aged women, though it can also occur in men. It is typically diagnosed in individuals between the ages of 40 and 60, often following routine blood tests that indicate liver abnormalities.

The global primary biliary cholangitis market was valued at $733.21 million in 2019 which grew till 2024 at a compound annual growth rate (CAGR) of more than 5.00%.

Rising Demand for Personalized Medicine

During the historic period, the rising demand for personalized medicine supported the growth of the primary biliary cholangitis market. Personalized medicine tailors treatments based on genetic, molecular and clinical profiles, enabling more precise therapies for primary biliary cholangitis. Obeticholic acid (OCA) serves as a targeted alternative to traditional treatments like ursodeoxycholic acid (UDCA). New therapies, including fibrates and FXR (farnesoid X receptor) agonists, are being evaluated for specific patient groups. Pharmacogenomics enhances treatment by predicting efficacy, minimizing side effects and reducing trial-and-error prescribing. This approach optimizes outcomes by ensuring patients receive the most effective, individualized therapy. For example, in October 2022, the Personalized Medicine Coalition, a US-based organization that represents scientists, patients and providers, promoting the understanding and adoption of personalized medicine to benefit patients and the healthcare system, estimated that more than 75,000 genetic testing products and 300 personalized medicines are on the market for people with multiple types of cancers, genetic rare diseases and a range of chronic and infectious diseases. Additionally, in 2022, according to the Personalized Medicine Coalition (PMC), a US-based company that advocates for personalized medicine, personalized medicines will account for 34% of new drug approvals by the US Food and Drug Administration in 2022 and have accounted for at least 25% of approvals in each of the previous eight years. Therefore, the rising demand for personalized

Role Of Combination Therapy In Liver Disease Management

Major companies operating in the primary biliary cholangitis market are focusing on introducing innovative therapies such as combination therapy to enhance treatment efficacy and improve patient outcomes in liver cancer care. Combination therapy refers to the use of two or more treatments or drugs together to target a specific condition, enhancing the overall therapeutic effect. For example, in June 2024, Ipsen Biopharmaceuticals, Inc., a France-based biopharmaceutical company received U.S. Food and Drug Administration (FDA) approval for Ipsen's Iqirvo (elafibranor) 80 mg (miligram) tablets for treating primary biliary cholangitis (PBC). This drug is a first-in-class PPAR (peroxisome proliferator-activated receptor) treatment. It is intended for use in combination with ursodeoxycholic acid (UDCA) for adults who do not respond adequately to UDCA, or as a monotherapy for patients who cannot tolerate UDCA.

The global primary biliary cholangitis market is highly concentrated, with large players operating in the market. The top ten competitors in the market made up to 50.90% of the total market in 2023.

Primary Biliary Cholangitis Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global primary biliary cholangitis market as it emerges from the COVID-19 shut down.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for primary biliary cholangitis? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The primary biliary cholangitis market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider primary biliary cholangitis market; and compares it with other markets.

The report covers the following chapters

  • Introduction And Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by treatment type, by diagnosis and by end user.
  • Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
  • Growth Analysis And Strategic Analysis Framework- Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
  • Regional And Country Analysis- Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
  • Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by treatment type, by diagnosis and by end user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
  • Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by exchange model, by trading type, by coin or token and by payment method in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
  • Regional Market Size And Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
  • Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
  • Other Major And Innovative Companies- Details on the company profiles of other major and innovative companies in the market.
  • Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
  • Competitive Dashboard- Briefs on competitive dashboard of major players.
  • Key Mergers And Acquisitions- Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
  • Recent Developments- Information on recent developments in the market covered in the report.
  • Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
  • Conclusions And Recommendations- This section includes recommendations for primary biliary cholangitis providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
  • Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

  • 1) By Treatment Type: Drugs; Liver Transplantation
  • 2)By Diagnosis: Magnetic Resonance Elastography (MRE); Magnetic Resonance Cholangiopancreatography (MRCP); Ultrasound; Fibroscan; Cholesterol Test; Antibody Tests; Liver Tests; Other Diagnoses
  • 3) By End User: Hospitals; Specialty Clinics; Homecare; Other End-Users
  • Companies Mentioned: Intercept Pharmaceuticals Inc.; Mayo Clinic Laboratories; University of Pittsburgh Medical Center (UPMC); Stanford Health Care; Duke University Hospital
  • Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia; Africa
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time-series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; primary biliary cholangitis indicators comparison.
  • Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

  • 1.1 Primary Biliary Cholangitis - Market Attractiveness And Macro Economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

  • 6.1 General Market Definition
  • 6.2 Summary
  • 6.3 Primary Biliary Cholangitis Market Definition And Segmentations
  • 6.4 Market Segmentation By Treatment Type
    • 6.4.1 Drugs
    • 6.4.2 Liver Transplantation
  • 6.5 Market Segmentation By Diagnosis
    • 6.5.1 Magnetic Resonance Elastography (MRE)
    • 6.5.2 Magnetic Resonance Cholangiopancreatography (MRCP)
    • 6.5.3 Ultrasound
    • 6.5.4 Fibroscan
    • 6.5.5 Cholesterol Test
    • 6.5.6 Antibody Tests
    • 6.5.7 Liver Tests
    • 6.5.8 Other Diagnoses
  • 6.6 Market Segmentation By End User
    • 6.6.1 Hospitals
    • 6.6.2 Specialty Clinics
    • 6.6.3 Homecare
    • 6.6.4 Other End-Users

7 Major Market Trends

  • 7.1 Role Of Combination Therapy In Liver Disease Management
  • 7.2 Advancements In Bile Acid Analog-Based Therapies
  • 7.3 Strategic Partnerships Driving Innovation In PBC Treatment

8 Global Primary Biliary Cholangitis Growth Analysis And Strategic Analysis Framework

  • 8.1 Global Primary Biliary Cholangitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
    • 8.1.1 Political
    • 8.1.2 Economic
    • 8.1.3 Social
    • 8.1.4 Technological
    • 8.1.5 Environmental
    • 8.1.6 Legal
  • 8.2 Analysis Of End Use Industries
    • 8.2.1 Hospitals And Specialty Clinics
    • 8.2.2 Homecare
    • 8.2.3 Diagnostic Laboratories
    • 8.2.4 Pharmaceutical & Biotechnology Companies
    • 8.2.5 Other End Users
  • 8.3 Global Primary Biliary Cholangitis Market Growth Rate Analysis
  • 8.4 Historic Market Growth, 2019 - 2024, Value ($ Million)
    • 8.4.1 Market Drivers 2019 - 2024
    • 8.4.2 Market Restraints 2019 - 2024
  • 8.5 Forecast Market Growth, 2024 - 2029, 2034F Value ($ Million)
    • 8.5.1 Market Drivers 2024 - 2029
    • 8.5.2 Market Restraints 2024 - 2029
  • 8.6 Forecast Growth Contributors/Factors
    • 8.6.1 Quantitative Growth Contributors
    • 8.6.2 Drivers
    • 8.6.3 Restraints
  • 8.7 Global Primary Biliary Cholangitis Total Addressable Market (TAM)

9 Global Primary Biliary Cholangitis Market Segmentation

  • 9.1 Global Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 9.2 Global Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 9.3 Global Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 9.4 Global Primary Biliary Cholangitis Market, Sub-Segmentation Of Drugs, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 9.5 Global Primary Biliary Cholangitis Market, Sub-Segmentation By Liver Transplantation, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

10 Primary Biliary Cholangitis Market, Regional and Country Analysis

  • 10.1 Global Primary Biliary Cholangitis Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 10.2 Global Primary Biliary Cholangitis Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

11 Asia-Pacific Market

  • 11.1 Summary
  • 11.2 Market Overview
    • 11.2.1 Region Information
    • 11.2.2 Market Information
    • 11.2.3 Background Information
    • 11.2.4 Government Initiatives
    • 11.2.5 Regulations
    • 11.2.6 Regulatory Bodies
    • 11.2.7 Major Associations
    • 11.2.8 Taxes Levied
    • 11.2.9 Corporate Tax Structure
    • 11.2.10 Investments
    • 11.2.11 Major Companies
  • 11.3 Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.4 Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.5 Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.6 Asia-Pacific Primary Biliary Cholangitis Market: Country Analysis
  • 11.7 China Market
  • 11.8 Summary
  • 11.9 Market Overview
    • 11.9.1 Country Information
    • 11.9.2 Market Information
    • 11.9.3 Background Information
    • 11.9.4 Government Initiatives
    • 11.9.5 Regulations
    • 11.9.6 Regulatory Bodies
    • 11.9.7 Major Associations
    • 11.9.8 Taxes Levied
    • 11.9.9 Corporate Tax Structure
    • 11.9.10 Investments
    • 11.9.11 Major Companies
  • 11.10 China Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.11 China Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.12 China Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.13 India Market
  • 11.14 India Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.15 India Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.16 India Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.17 Japan Market
  • 11.18 Summary
  • 11.19 Market Overview
    • 11.19.1 Country Information
    • 11.19.2 Market Information
    • 11.19.3 Background Information
    • 11.19.4 Government Initiatives
    • 11.19.5 Regulations
    • 11.19.6 Regulatory Bodies
    • 11.19.7 Major Associations
    • 11.19.8 Taxes Levied
    • 11.19.9 Corporate Tax Structure
    • 11.19.10 Major Companies
  • 11.20 Japan Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.21 Japan Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.22 Japan Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.23 Australia Market
  • 11.24 Australia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.25 Australia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.26 Australia Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.27 Indonesia Market
  • 11.28 Indonesia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.29 Indonesia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.30 Indonesia Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.31 South Korea Market
  • 11.32 Summary
  • 11.33 Market Overview
    • 11.33.1 Country Information
    • 11.33.2 Market Information
    • 11.33.3 Background Information
    • 11.33.4 Government Initiatives
    • 11.33.5 Regulations
    • 11.33.6 Regulatory Bodies
    • 11.33.7 Major Associations
    • 11.33.8 Taxes Levied
    • 11.33.9 Corporate Tax Structure
    • 11.33.10 Major Companies
  • 11.34 South Korea Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.35 South Korea Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.36 South Korea Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

12 Western Europe Market

  • 12.1 Summary
  • 12.2 Market Overview
    • 12.2.1 Region Information
    • 12.2.2 Market Information
    • 12.2.3 Background Information
    • 12.2.4 Government Initiatives
    • 12.2.5 Regulations
    • 12.2.6 Regulatory Bodies
    • 12.2.7 Major Associations
    • 12.2.8 Taxes Levied
    • 12.2.9 Corporate tax structure
    • 12.2.10 Investments
    • 12.2.11 Major Companies
  • 12.3 Western Europe Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.4 Western Europe Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.5 Western Europe Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.6 Western Europe Primary Biliary Cholangitis Market: Country Analysis
  • 12.7 UK Market
  • 12.8 UK Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.9 UK Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.10 UK Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.11 Germany Market
  • 12.12 Germany Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.13 Germany Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.14 Germany Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.15 France Market
  • 12.16 France Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.17 France Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.18 France Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.19 Italy Market
  • 12.20 Italy Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.21 Italy Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.22 Italy Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.23 Spain Market
  • 12.24 Spain Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.25 Spain Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.26 Spain Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

13 Eastern Europe Market

  • 13.1 Summary
  • 13.2 Market Overview
    • 13.2.1 Region Information
    • 13.2.2 Market Information
    • 13.2.3 Background Information
    • 13.2.4 Government Initiatives
    • 13.2.5 Regulations
    • 13.2.6 Regulatory Bodies
    • 13.2.7 Major Associations
    • 13.2.8 Taxes Levied
    • 13.2.9 Corporate Tax Structure
    • 13.2.10 Major companies
  • 13.3 Eastern Europe Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.4 Eastern Europe Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.5 Eastern Europe Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.6 Eastern Europe Primary Biliary Cholangitis Market: Country Analysis
  • 13.7 Russia Market
  • 13.8 Russia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.9 Russia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.10 Russia Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

14 North America Market

  • 14.1 Summary
  • 14.2 Market Overview
    • 14.2.1 Region Information
    • 14.2.2 Market Information
    • 14.2.3 Background Information
    • 14.2.4 Government Initiatives
    • 14.2.5 Regulations
    • 14.2.6 Regulatory Bodies
    • 14.2.7 Major Associations
    • 14.2.8 Taxes Levied
    • 14.2.9 Corporate Tax Structure
    • 14.2.10 Investments
    • 14.2.11 Major Companies
  • 14.3 North America Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.4 North America Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.5 North America Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.6 North America Primary Biliary Cholangitis Market: Country Analysis
  • 14.7 USA Market
  • 14.8 Summary
  • 14.9 Market Overview
    • 14.9.1 Country Information
    • 14.9.2 Market Information
    • 14.9.3 Background Information
    • 14.9.4 Government Initiatives
    • 14.9.5 Regulations
    • 14.9.6 Regulatory Bodies
    • 14.9.7 Major Associations
    • 14.9.8 Taxes Levied
    • 14.9.9 Corporate Tax Structure
    • 14.9.10 Investments
    • 14.9.11 Major Companies
  • 14.10 USA Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.11 USA Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.12 USA Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.13 Canada Market
  • 14.14 Summary
  • 14.15 Market Overview
    • 14.15.1 Country Information
    • 14.15.2 Market Information
    • 14.15.3 Background Information
    • 14.15.4 Government Initiatives
    • 14.15.5 Regulations
    • 14.15.6 Regulatory Bodies
    • 14.15.7 Major Associations
    • 14.15.8 Taxes Levied
    • 14.15.9 Corporate Tax Structure
    • 14.15.10 Major Companies
  • 14.16 Canada Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.17 Canada Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.18 Canada Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

15 South America Market

  • 15.1 Summary
  • 15.2 Market Overview
    • 15.2.1 Region Information
    • 15.2.2 Market Information
    • 15.2.3 Background Information
    • 15.2.4 Government Initiatives
    • 15.2.5 Regulations
    • 15.2.6 Regulatory Bodies
    • 15.2.7 Major Associations
    • 15.2.8 Taxes Levied
    • 15.2.9 Corporate Tax Structure
    • 15.2.10 Investments
    • 15.2.11 Major Companies
  • 15.3 South America Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.4 South America Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.5 South America Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.6 South America Primary Biliary Cholangitis Market: Country Analysis
  • 15.7 Brazil Market
  • 15.8 Brazil Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.9 Brazil Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.10 Brazil Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

16 Middle East Market

  • 16.1 Summary
  • 16.2 Market Overview
    • 16.2.1 Region Information
    • 16.2.2 Market Information
    • 16.2.3 Background Information
    • 16.2.4 Government Initiatives
    • 16.2.5 Regulations
    • 16.2.6 Regulatory Bodies
    • 16.2.7 Major Associations
    • 16.2.8 Taxes Levied
    • 16.2.9 Corporate Tax Structure
    • 16.2.10 Major Companies
  • 16.3 Middle East Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.4 Middle East Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.5 Middle East Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

17 Africa Market

  • 17.1 Summary
  • 17.2 Market Overview
    • 17.2.1 Region Information
    • 17.2.2 Market Information
    • 17.2.3 Background Information
    • 17.2.4 Government Initiatives
    • 17.2.5 Regulations
    • 17.2.6 Regulatory Bodies
    • 17.2.7 Major Associations
    • 17.2.8 Taxes Levied
    • 17.2.9 Corporate Tax Structure
    • 17.2.10 Major Companies
  • 17.3 Africa Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 17.4 Africa Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 17.5 Africa Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

18 Competitive Landscape and Company Profiles

  • 18.1 Company Profiles
  • 18.2 Intercept Pharmaceuticals Inc.
    • 18.2.1 Company Overview
    • 18.2.2 Products And Services
    • 18.2.3 Business Strategy
    • 18.2.4 Financial Overview
  • 18.3 Mayo Clinic Laboratories
    • 18.3.1 Company Overview
    • 18.3.2 Products And Services
    • 18.3.3 Business Strategy
    • 18.3.4 Financial Overview
  • 18.4 University of Pittsburgh Medical Center (UPMC)
    • 18.4.1 Company Overview
    • 18.4.2 Products And Services
    • 18.4.3 Financial Overview
  • 18.5 Stanford Health Care
    • 18.5.1 Company Overview
    • 18.5.2 Products And Services
    • 18.5.3 Financial Overview
  • 18.6 Duke University Hospital
    • 18.6.1 Company Overview
    • 18.6.2 Products And Services
    • 18.6.3 Financial Overview

19 Other Major And Innovative Companies

  • 19.1 UCLA Medical Center
    • 19.1.1 Company Overview
    • 19.1.2 Products and Services
  • 19.2 King's College Hospital
    • 19.2.1 Company Overview
    • 19.2.2 Products and Services
  • 19.3 NewYork-Presbyterian Hospital
    • 19.3.1 Company Overview
    • 19.3.2 Products and Services
  • 19.4 Cleveland Clinic
    • 19.4.1 Company Overview
    • 19.4.2 Products and Services
  • 19.5 Johns Hopkins Hospital
    • 19.5.1 Company Overview
    • 19.5.2 Products and Services
  • 19.6 GENFIT S.A
    • 19.6.1 Company Overview
    • 19.6.2 Products and Services
  • 19.7 Ipsen Pharma SA
    • 19.7.1 Company Overview
    • 19.7.2 Products and Services
  • 19.8 Gilead Sciences Inc.
    • 19.8.1 Company Overview
    • 19.8.2 Products and Services
  • 19.9 Ascletis Pharma Inc.
    • 19.9.1 Company Overview
    • 19.9.2 Products and Services
  • 19.10 Calliditas Therapeutics AB
    • 19.10.1 Company Overview
    • 19.10.2 Products and Services
  • 19.11 Cour Pharmaceutical
    • 19.11.1 Company Overview
    • 19.11.2 Products and Services
  • 19.12 GlaxoSmithKline plc (GSK)
    • 19.12.1 Company Overview
    • 19.12.2 Products and Services
  • 19.13 HighTide Biopharma Inc.
    • 19.13.1 Company Overview
    • 19.13.2 Products and Services
  • 19.14 Mirum Pharmaceuticals Inc.
    • 19.14.1 Company Overview
    • 19.14.2 Products and Services
  • 19.15 NGM Biopharmaceuticals Inc.
    • 19.15.1 Company Overview
    • 19.15.2 Products and Services

20 Competitive Benchmarking

21 Competitive Dashboard

22 Key Mergers And Acquisitions

  • 22.1 Gilead Sciences Acquired CymaBay Therapeutics
  • 22.2 Alfasigma Acquired Intercept Pharmaceuticals
  • 22.3 Ipsen Acquired Albireo Pharma
  • 22.4 Advanz Pharma Corp. Limited Acquired Intercept Pharmaceuticals

23 Recent Development In Primary Biliary Cholangitis Market

  • 23.1 Orphan Drug Designation To CNP-104 For Primary Biliary Cholangitis
  • 23.2 FDA Grants Accelerated Approval To Seladelpar For Primary Biliary Cholangitis

24 Opportunities And Strategies

  • 24.1 Global Primary Biliary Cholangitis Market In 2029 - Countries Offering Most New Opportunities
  • 24.2 Global Primary Biliary Cholangitis Market In 2029 - Segments Offering Most New Opportunities
  • 24.3 Global Primary Biliary Cholangitis Market In 2029 - Growth Strategies
    • 24.3.1 Market Trend Based Strategies
    • 24.3.2 Competitor Strategies

25 Primary Biliary Cholangitis Market, Conclusions And Recommendations

  • 25.1 Conclusions
  • 25.2 Recommendations
    • 25.2.1 Product
    • 25.2.2 Place
    • 25.2.3 Price
    • 25.2.4 Promotion
    • 25.2.5 People

26 Appendix

  • 26.1 Geographies Covered
  • 26.2 Market Data Sources
  • 26.3 Research Methodology
  • 26.4 Currencies
  • 26.5 The Business Research Company
  • 26.6 Copyright and Disclaimer